Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 5Terminated 4Active not recruiting 3Withdrawn 2Recruiting 2Not yet recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Myeloid 3Other hematologic neoplasm 1

Conditions

Breast Neoplasms 704Carcinoma, Non-Small-Cell Lung 470Prostatic Neoplasms 420Neoplasms 380Multiple Myeloma 264Colorectal Neoplasms 261Lung Neoplasms 247Neoplasm Metastasis 229Melanoma 215Ovarian Neoplasms 191Leukemia, Myeloid, Acute 189Pancreatic Neoplasms 182Squamous Cell Carcinoma of Head and Neck 163Recurrence 147Carcinoma, Renal Cell 145Lymphoma 142Glioblastoma 138Lymphoma, Non-Hodgkin 135Stomach Neoplasms 128Triple Negative Breast Neoplasms 127Brain Neoplasms 124Carcinoma, Hepatocellular 123Leukemia, Lymphocytic, Chronic, B-Cell 122Uterine Cervical Neoplasms 117Head and Neck Neoplasms 117Precursor Cell Lymphoblastic Leukemia-Lymphoma 115Urinary Bladder Neoplasms 113Lymphoma, Large B-Cell, Diffuse 105Sarcoma 102Lymphoma, Follicular 100

Interventions

venetoclax 1pevonedistat 1imetelstat 1GRN163L peptide 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × Thrombocytosis × Clear all
NCT03862157 2026-03-11

Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
40 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT04576156 2025-12-04

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

Geron Corporation

Phase 3 Active not recruiting
327 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia, Thrombocytosis, Primary Myelofibrosis

NCT05482971 2025-08-13

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET

PharmaEssentia

Phase 2 Active not recruiting
91 enrolled
Myeloid

Myeloproliferative Disorders, Neoplasms, Thrombocythemia, Essential, Thrombocytosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡